Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy
Part of paid clinical trials in Gainesville, Florida.
- Sponsor
- University of Florida
- Study ID
- NCT06184516
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Urothelial Carcinoma Bladder
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 99 Years
- Healthy Volunteers
- Not accepted
Interventions
- Reproductive organ sparing radical cystectomy — PROCEDUREParticipants on this arm will undergo a reproductive organ sparing radical cystectomy if they are classified as "favorable" based on the decision tool.
- Radical cystectomy — PROCEDUREParticipants on this arm will undergo a radical cystectomy if they are classified as "unfavorable" based on the decision tool.
Study Details
Currently, the standard of care for female patients undergoing radical cystectomy includes the removal of the bladder, pelvic lymph nodes, anterior vagina, uterus, fallopian tubes and ovaries. Removal of female ancillary organs, both in pre and post-menopausal stages is associated with reduction in various quality of life metrics, including sexual health, cognitive decline and depression. Furthermore, removal of ovaries has been associated with increased cardiovascular events, metabolic acidosis, osteoporosis and bone fractures. In premenopausal women, the removal of the ovaries is associated with increased all-cause mortality. From an oncologic standpoint, multi institutional retrospective reviews have demonstrated certain pre-operative radiographic and cystoscopic risk factors that are associated with bladder cancer involvement of female reproductive organs. The absence of these unfavorable risk factors may provide an opportunity to spare women from undergoing unnecessary reproductive organ removal during RC. In doing so, this may eliminate the associated sequelae of removing these additional organs while also providing acceptable oncologic care. The investigators thus propose a decision tool to stratify women undergoing radical cystectomy as favorable and unfavorable for reproductive organ sparing radical cystectomy. This decision tool classification will be used to decide which patients will undergo reproductive organ sparing radical cystectomy versus radical cystectomy in this study.
Key Dates
- Start date
- Aug 30, 2024
- Status verified
- Jun 2026
- Primary completion
- Mar 31, 2027
- Completion
- Mar 31, 2028
Study Design
- Enrollment
- 127 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Reproductive organ sparing radical cystectomy
- Active Comparator: Radical cystectomy
Primary Outcome Measure
Positive margin rate [ Time Frame: 120 days ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Florida | Gainesville | Florida | 32608 | Tarik Benidir, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Gainesville, FL
Related Studies
- A Study of VET3-TGI in Patients With Solid TumorsPHASE1 · Recruiting · KaliVir Immunotherapeutics · Los Angeles, California
- A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsPHASE1 · Recruiting · Aktis Oncology, Inc. · Duarte, California
- Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder CancerPHASE2 · Recruiting · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Washington D.C., District of Columbia
- A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder CancerPHASE1 · Recruiting · Aura Biosciences · Little Rock, Arkansas